Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 19/20 | 1.00 |
| ▸ | AKR1C1 | Q04828 | 5/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.82 |
| ▸ | MEN1 | O00255 | 1/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30819658 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C1ALDH1A1MEN1KMT2A | |
| SCHEMBL14943437 | 0.88 | AKR1C3 (0.79) | AKR1C3AKR1C1ALDH1A1MEN1KMT2A | |
| SCHEMBL3280649 | 0.85 | AKR1C3 (0.76) | AKR1C3AKR1C1MEN1KMT2A | |
| SCHEMBL4239496 | 0.85 | AKR1C3 (0.76) | AKR1C3AKR1C1ALDH1A1MEN1KMT2A | |
| SCHEMBL12401136 | 0.85 | AKR1C3 (0.74) | AKR1C3AKR1C1ALDH1A1MEN1KMT2A | |
| SCHEMBL21067755 | 0.83 | PPARG (1.00) | AKR1C3AKR1C1MEN1KMT2A | |
| SCHEMBL693455 | 0.83 | KMT2A (1.00) | AKR1C3AKR1C1ALDH1A1MEN1KMT2A | |
| Thiophene Carboxylic Acid SCHEMBL29135076 | 0.82 | AKR1C3 (0.77) | AKR1C3AKR1C1ALDH1A1MEN1KMT2A | |
| SCHEMBL3287776 | 0.79 | AKR1C3 (0.66) | AKR1C3AKR1C1 | |
| SCHEMBL663840 | 0.79 | AKR1C3 (1.00) | AKR1C3AKR1C1ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11215617-B2 | Treatment of metastatic prostate cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-01-04 | — | — | US | disclosed |
| EP-3062808-B1 | TREATMENT OF METASTATIC PROSTATE CANCER | UNIV CALIFORNIA (US) | 2021-09-29 | — | — | EP | disclosed |
| US-20200041516-A1 | TREATMENT OF METASTATIC PROSTATE CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-02-06 | — | — | US | disclosed |
| US-20170315127-A1 | TREATMENT OF METASTATIC PROSTATE CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-11-02 | — | — | US | disclosed |
| EP-3062808-A1 | TREATMENT OF METASTATIC PROSTATE CANCER | The Regents of the University of California (US) | 2016-09-07 | — | — | EP | disclosed |
| WO-2015065919-A1 | TREATMENT OF METASTATIC PROSTATE CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-05-07 | — | — | WO | disclosed |
| EP-2366704-B1 | Inhibitors of serine proteases | VERTEX PHARMA (US) | 2013-10-23 | — | — | EP | disclosed |
| EP-2631238-A1 | Spirocyclic inhibitors of serine proteases for the treatment of hcv infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-28 | — | — | EP | disclosed |
| US-8440706-B2 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-05-14 | — | — | US | disclosed |
| US-8372873-B2 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-12 | — | — | US | disclosed |
| EP-1917269-B1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMA (US) | 2011-10-26 | — | — | EP | disclosed |
| EP-2366704-A1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-21 | — | — | EP | disclosed |
| US-20110182856-A1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-28 | — | — | US | disclosed |
| US-7985762-B2 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-26 | — | — | US | disclosed |
| US-20110165120-A1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-07 | — | — | US | disclosed |
| US-7964624-B1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-21 | — | — | US | disclosed |
| US-20070179167-A1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11215617-B2 | Treatment of metastatic prostate cancer | AR, AKR1C3, AKR1C4 | AKR1C3 2/4885AKR1C1 5/4885ALDH1A1 154/4885 |
| US-20170315127-A1 | TREATMENT OF METASTATIC PROSTATE CANCER | AR, AKR1C3, AKR1C4 | AKR1C3 2/4885AKR1C1 5/4885ALDH1A1 154/4885 |
| US-20110165120-A1 | INHIBITORS OF SERINE PROTEASES | PRSS1, PRSS3, PRSS2 | AKR1C3 2474/4885AKR1C1 2859/4885ALDH1A1 1374/4885 |
| US-20070179167-A1 | Inhibitors of serine proteases | PRSS1, PRSS3, PRSS2 | AKR1C3 2474/4885AKR1C1 2859/4885ALDH1A1 1374/4885 |
| US-20200041516-A1 | TREATMENT OF METASTATIC PROSTATE CANCER | AR, AKR1C3, AKR1C4 | AKR1C3 2/4885AKR1C1 5/4885ALDH1A1 154/4885 |
| US-20110182856-A1 | INHIBITORS OF SERINE PROTEASES | PRSS1, SPINT2, PRSS2 | AKR1C3 2282/4885AKR1C1 2653/4885ALDH1A1 1255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.